SCHEMBL7180724

SCHEMBL7180724

CCOc1ccc(PC(=O)c2c(C)cccc2Cl)c(C)c1.[LiH]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.39
MEN1 O00255 1/20 0.38
PKM P14618 1/20 0.38
KMT2A Q03164 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
ALDH1A1 P00352 4/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
ATM Q13315 1/20 0.36
NOTUM Q6P988 1/20 0.36
FADS1 O60427 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TRPM4 Q8TD43 1/20 0.36
DYRK1A Q13627 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188792 0.96 MCL1 (0.42) MCL1MEN1PKMKMT2AMRGPRX4
SCHEMBL7177209 0.91 SMN1; SMN2 (0.41) PKMKMT2AMRGPRX4ALDH1A1SMN1; SMN2
SCHEMBL7177244 0.91 KDM4E (0.40) MCL1MEN1PKMKMT2AALDH1A1
SCHEMBL7183768 0.91 KMT2A (0.40) MCL1MEN1KMT2AMRGPRX4ALDH1A1
SCHEMBL7180649 0.91 MCL1 (0.40) MCL1MRGPRX4ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7180489 0.90 FFAR1 (0.44) MCL1MEN1KMT2AALDH1A1KDM4E
SCHEMBL7174867 0.90 SMN1; SMN2 (0.46) MCL1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL7182236 0.89 THRA (0.41) MCL1MRGPRX4
Lithium SCHEMBL7177249 0.88 KDM4E (0.40) MCL1MEN1PKMKMT2AALDH1A1
SCHEMBL7183264 0.88 THRB (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MCL1 339/4885MEN1 2312/4885PKM 3848/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MCL1 420/4885MEN1 2263/4885PKM 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.